Alpha-1 antitrypsin augmentation therapy

COPD: Journal of Chronic Obstructive Pulmonary Disease

Volumn 10, Issue S1, 2013, Pages 64-67

  Wewers, Mark D ^a   Crystal, Ronald G ^b  

^a OHIO STATE UNIVERSITY   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Alpha 1 antitrypsin; Augmentation therapy; Pulmonary genetic disease

Indexed keywords

ALPHA 1 ANTITRYPSIN;

ALPHA 1 ANTITRYPSIN DEFICIENCY; BIOLOGICAL THERAPY; CLINICAL STUDY; CLINICAL TRIAL (TOPIC); DRUG APPROVAL; DRUG EFFICACY; DRUG INDUSTRY; DRUG SAFETY; FEASIBILITY STUDY; HUMAN; LUNG ALVEOLUS EPITHELIUM; LUNG EMPHYSEMA; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW;

ALPHA 1-ANTITRYPSIN; ALPHA 1-ANTITRYPSIN DEFICIENCY; EVIDENCE-BASED MEDICINE; HUMANS; REGISTRIES; SERINE PROTEINASE INHIBITORS;

EID: 84875668547     PISSN: 15412555     EISSN: 15412563     Source Type: Journal    
DOI: 10.3109/15412555.2013.764402     Document Type: Review

References (28)

1. Gadek JE, Klein HG, Holland PV, Crystal RG. Replacement therapy of alpha-1antitrypsin deficiency: reversal of proteaseantiprotease imbalance within the alveolar structures of PiZ subjects. J Clin Invest 1981; 68:1158-1165.
2. Gadek JE, Hosea SW, Gelfand JA, Santaella M, Wickerhauser M, Triantaphyllopoulos DC, et al. Replacement therapy in hereditary angioedema: successful treatment of acute episodes of angioedema with partly purified C1 inhibitor. N Engl J Med 1980; 302(10):542-546.
3. Walker EW. On the protective substances of immune sera. J Hyg (Lond) 1902; 2(1):85-100.
4. Dwyer JM. Manipulating the immune system with immune globulin. N Engl J Med 1992; 326(2):107-116.
5. Cohen H, Kernoff PB. ABC of transfusion. Plasma, plasma products, and indications for their use. Br Med J 1990; 300(6727):803-806.
6. Cohn EJ, Oncley JL, Strong LE, Hughes WL, Armstrong SH. Chemical, clinical, and immunological studies on the products of human plasma fractionation. I. The characterizatio of the protein fractions of human plasma. J Clin Invest 1944; 23(4):417-432.
7. Laurell C-B, Eriksson S. The electrophoretic alpha-1-globulin pattern of serum in alpha-1 antitrypsin deficiency. Scand J Clin Lab Invest 1963; 15:132-140.
8. Eriksson S. Studies in alpha-1 antitrypsin deficiency. Acta Med Scand 1965; Supplement 432:5-85.
9. Wright GW, Kleinerman J. The J. Burns Amberson Lecture 1-4. A consideration of the etiology of emphysema in terms of contemporary knowledge. Am Rev Respir Dis 1963; 88:605- 620.
10. Gross P, Pfitzer EA, Tolker E, Babyak M, Kaschak M. Experimental emphysema: its production with papain in normal and silicotic rats. Arch Environ Health 1965; 11:50- 59.
11. Silverman EK, Pierce JA, Province MA, Rao DC, Campbell EJ. Variability of pulmonary function in alpha-1 antitrypsin deficiency: clinical correlates. Ann Intern Med 1989; 111(12):982-991.
12. Silverman EK, Miletich JP, Pierce JA, Sherman LA, Endicott SK, Broze GJ, Jr., et al. Alpha-1 antitrypsin deficiency. High prevalence in the St. Louis area determined by direct population screening. Am Rev Respir Dis 1989; 140(4):961- 966.
13. Janus ED, Phillips NT, Carrell RW. Smoking, lung function, and alpha-1 antitrypsin deficiency. Lancet 1985; 1(8421):152- 154.
14. Larsson C. Natural history and life expectancy in severe alpha-1 antitrypsin deficiency, Pi Z. Acta Med Scand 1978; 204(5):345-351.
15. Hersh CP, Dahl M, Ly NP, Berkey CS, Nordestgaard BG, Silverman EK. Chronic obstructive pulmonary disease in alpha-1 antitrypsin PI*MZ heterozygotes: a meta-analysis. Thorax 2004; 59(10):843-849.
16. Morse JO, Lebowitz MD, Knudson RJ, Burrows B. Relation of protease inhibitor phenotypes to obstructive lung diseases in a community. NEJM 1977; 296:1190-1194.
17. Hutchison DC, Tobin MJ, Cook PJ. Alpha-1 antitrypsin deficiency: clinical and physiological features in heterozygotes of PI* type SZ. A survey by the British Thoracic Association. Br J Dis Chest 1983; 77(1):28-34.
18. Larsson C, Dirksen H, Sundstrom G, Eriksson S. Lung function studies in asymptomatic individuals with moderately (PI*SZ) and severely (PI*Z) reduced levels of alpha-1 antitrypsin. Scand J Respir Dis 1976; 57(6):267-280.
19. Turino GM, Barker AF, Brantly ML, Cohen AB, Connelly RP, Crystal RG, et al. Clinical features of individuals with PI*SZ phenotype of alpha-1antitrypsin deficiency. alpha-1 Antitrypsin Deficiency Registry Study Group. Am J Respir Crit Care Med 1996 Dec; 154(6 Pt 1):1718-1725.
20. American Thoracic Society/European Respiratory Society statement: standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency. Am J Respir Crit Care Med 2003 Oct 1; 168(7):818-900.
21. Jones EA, Vergalla J, Steer CJ, Bradley-Moore PR, Vierling JM. Metabolism of intact and desialylated alpha-1 antitrypsin. Clin Sci Mol Med 1978; 55:139.
22. Wewers MD, Casolaro MA, Sellers SE, Swayze SC, McPhaul KM, Wittes JT, et al. Replacement therapy for alpha-1 antitrypsin deficiency associated with emphysema. N Engl J Med 1987; 316:1055-1062.
23. Hubbard RC, Sellers S, Czerski D, Stephens L, Crystal RG. Biochemical efficacy and safety of monthly augmentation therapy for alpha-1 antitrypsin deficiency. JAMA 1988; 260(9):1259-1264.
24. Schmidt EW, Rasche B, Ulmer WT, Konietzko N, Becker M, Fallise JP, et al. Replacement therapy for alpha-1-protease inhibitor deficiency in PI*Z subjects with chronic obstructive lung disease. Am J Med 1988; 84(6A):63-69.
25. Survival and FEV1 decline in individuals with severe deficiency of alpha1-antitrypsin. The Alpha-1-Antitrypsin Deficiency Registry Study Group. Am J Respir Crit Care Med 1998; 158(1):49-59.
26. Dirksen A, Dijkman JH, Madsen F, Stoel B, Hutchison DC, Ulrik CS, et al. A randomized clinical trial of alpha-1 antitrypsin augmentation therapy. Am J Respir Crit Care Med 1999; 160(5 Pt 1):1468-1472.
27. Dirksen A, Piitulainen E, Parr DG, Deng C, Wencker M, Shaker SB, et al. Exploring the role of CT densitometry: a randomised study of augmentation therapy in alpha-1 antitrypsin deficiency. Eur Respir J 2009; 33(6):1345-1353.
28. Gotzsche PC, Johansen HK. Intravenous alpha-1 antitrypsin augmentation therapy for treating patients with alpha-1 antitrypsin deficiency and lung disease. Cochrane Database Syst Rev 2010; (7):CD007851.